Analysis of the outcome of concurrent neoadjuvant chemoradiotherapy with S-1 compared to super-selective intra-arterial infusion for oral squamous cell carcinoma.

We introduced concurrent neoadjuvant chemoradiotherapy (CCRT) with S-1, an oral fluoropyrimidine, as treatment for oral squamous cell carcinoma (OSCC) from October 2005. The clinical usefulness and medical safety of CCRT with S-1 (S-1 group) for OSCC were analyzed and compared with CCRT using super-selective intra-arterial infusion (AI group). The subjects in the S-1 group underwent external irradiation, at a total dose of 30 Gy, with S-1 chemotherapy. The AI group received cisplatin (CDDP) or carboplatin (CBDCA) combined with daily radiotherapy at a total dose of 40 Gy. The histological effects and disease-specific survival rates were almost equivalent in the S-1 and AI groups. Adverse events were less frequent in the S-1 group, while hematological toxicity, including anemia, thrombopenia and pharyngeal edema, was observed in the AI group. The results of this study indicate that CCRT combined with S-1 is a more effective and safer treatment for OSCC than AI.

[1]  Y. Kuratomi,et al.  [A comparative study of concurrent chemoradiotherapy with S-1 or CDDP for pharyngeal or laryngeal cancer]. , 2010, Gan to kagaku ryoho. Cancer & chemotherapy.

[2]  晃治 岸本,et al.  口腔進行癌に対するTS-1 と放射線同時併用療法 , 2009 .

[3]  H. Shinkawa,et al.  [Treatment results of chemotherapy with S-1 for head and neck cancer]. , 2009, Gan to kagaku ryoho. Cancer & chemotherapy.

[4]  T. Shirasaka.  Development History and Concept of an Oral Anticancer Agent S-1 (TS-1®): Its Clinical Usefulness and Future Vistas , 2008, Japanese journal of clinical oncology.

[5]  M. Hiraoka,et al.  TS‐1 enhances the effect of radiotherapy by suppressing radiation‐induced hypoxia‐inducible factor‐1 activation and inducing endothelial cell apoptosis , 2008, Cancer science.

[6]  Y. Nagano,et al.  [A case of interstitial pneumonia after S-1 administration for gastric cancer]. , 2008, Gan to kagaku ryoho. Cancer & chemotherapy.

[7]  I. Tohnai,et al.  Daily concurrent chemoradiotherapy with docetaxel (DOC) and cisplatin (CDDP) using superselective intra-arterial infusion via superficial temporal artery for T3 and T4 head and neck cancer: Possibility of organ preservation in advanced head and neck cancer. , 2008, Journal of Clinical Oncology.

[8]  M. Voracek,et al.  Preoperative chemoradiotherapy in the management of oral cancer: a review. , 2008, Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery.

[9]  憲幸 山本,et al.  浅側頭動脈よりの超選択的動注法（HFT法）を用いた連日同時放射線化学療法 , 2007 .

[10]  A. Kida,et al.  [Long-term results of S-1 administration as adjuvant chemotherapy for advanced head and neck cancer]. , 2007, Gan to kagaku ryoho. Cancer & chemotherapy.

[11]  K. Harada,et al.  [A case of advanced oral squamous cell carcinoma responding to concurrent radiotherapy with S-1]. , 2007, Gan to kagaku ryoho. Cancer & chemotherapy.

[12]  K. Dietz,et al.  Bmc Cancer , 2022 .

[13]  I. Tohnai.  [Intra-arterial chemotherapy for head and neck cancer]. , 2005, Gan to kagaku ryoho. Cancer & chemotherapy.

[14]  弘之 立花,et al.  浅側頭動脈カテーテルからの持続動注と放射線治療の併用療法 : III, IV期舌癌を中心として , 2005 .

[15]  A. Kida,et al.  [Intraarterial concomitant chemoradiation for tongue cancer: analysis of 20 patients]. , 2005, Nihon Jibiinkoka Gakkai kaiho.

[16]  M. van Glabbeke,et al.  Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. , 2004, The New England journal of medicine.

[17]  T. Harada,et al.  SUPERSELECTIVE INTRAARTERIAL CHEMOTHERAPY USING CISPLATIN (CDDP)-CARBOPLATIN (CBDCA) COMBINED WITH RADIOTHERAPY FOR HEAD AND NECK CANCERS , 2003 .

[18]  K. Shiga,et al.  SUPERSELECTIVE INTRAARTERIAL CHEMOTHERAPY FOR PATIENTS WITH HEAD AND NECK TUMOR , 2003 .

[19]  O. Matsui,et al.  SUPERSELECTIVE INTRA-ARTERIAL CHEMOTHERAPY FOR HEAD AND NECK SQUAMOUS CELL CARCINOMA , 2003 .

[20]  T. Kirita,et al.  Primary tumour resection of tongue carcinoma based on response to preoperative therapy. , 2002, International journal of oral and maxillofacial surgery.

[21]  N. Fuwa.  [Current and future state of chemoradiotherapy for head and neck cancer]. , 2002, Nihon Igaku Hoshasen Gakkai zasshi. Nippon acta radiologica.

[22]  H. Honda,et al.  Concurrent chemoradiotherapy with S-1 as first-line treatment for patients with oropharyngeal cancer. , 2011, Journal of radiation research.

[23]  Y. Yoshihama,et al.  Concurrent chemoradiotherapy with TS-1 for advanced oral cancer : Feasibility, problems, and countermeasures for elderly patients with complications , 2009 .

[24]  E. Vokes,et al.  Expanding Role of the Medical Oncologist in the Management of Head and Neck Cancer , 2008, CA: a cancer journal for clinicians.

[25]  I. Tohnai,et al.  DAILY CONCURRENT CHEMORADIOTHERAPY USING SUPERSELECTIVE INTRA-ARTERIAL INFUSION VIA SUPERFICIAL TEMPORAL ARTERY-PREOPERATIVE THERAPY FOR STAGE III, IV ORAL CANCER- , 2005 .

[26]  H. Spoendlin,et al.  The effect of chemotherapy in relation to pathohistological tumour grading in head and neck cancer , 2004, Archives of oto-rhino-laryngology.

[27]  Y. Shimosato,et al.  Histological Evaluation of Effects of Radiotherapy and Chemotherapy for carcinomas , 1971 .